四环医药(00460.HK) 公布，与韩国生物制药公司Hugel, Inc.签署的关于注射用A型肉毒毒素(乐提葆)的独家销售协议，经协议双方一致确认，已续约至2030年年底。
据介绍，乐提葆是中国市场中第四个获批上市的肉毒毒素产品，也是目前中国市场上唯一一个获批的韩国肉毒毒素产品，该产品由Hugel, Inc.研发生产。
今年上半年，乐提葆在中国的销售收入按年增长逾50%。根据市场信息显示，乐提葆在中国的市场占有率已超过10%。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-09-26 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.